Back to School: How biopharma can reboot drug development. Access exclusive analysis here

One deal at a time

Orexo AB is acquiring Biolipox AB to add critical mass and put the company in a better position for future M&A. Orexo hopes a future purchase of a sales and marketing company will enable it to integrate forward to become a specialty pharma.

Last Monday, Orexo (SSE:ORX, Uppsala, Sweden) said it would acquire Biolipox (Stockholm, Sweden) for 8.6 million shares of ORX stock, which values the inflammation, neurology and pulmonary company at SEK776.8 million ($120.9

Read the full 744 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE